Method of administration of paclitaxel-plasma protein formulation
The present invention provides for a method for treating human or animal patients with paclitaxel formulation, the method comprising an intratumoral dose of a paclitaxel formulation and an intravenous dose of paclitaxel. The intravenous dose occurs about 1 to about 7 days after the intratumoral dose...
Gespeichert in:
| 1. Verfasser: | |
|---|---|
| Format: | Patent |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext bestellen |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| Zusammenfassung: | The present invention provides for a method for treating human or animal patients with paclitaxel formulation, the method comprising an intratumoral dose of a paclitaxel formulation and an intravenous dose of paclitaxel. The intravenous dose occurs about 1 to about 7 days after the intratumoral dose. The paclitaxel formulation may typically be either a paclitaxel/HSA formulation or paclitaxel/gamma-globulin formulation. |
|---|